Bitcoin
79105.26
-1974.13
-2.5%
Crude Oil
101.12
-0.05
-0.05%
Gold
4554.2
-131.1
-2.88%
Copper
6.29
-0.32
-5.14%
Silver
76.92
-7.7
-10.01%
Dow Jones
49693.21
-67.36
-0.14%
SP500
7420.82
-80.42
-1.08%
NASDAQ
26402.34
+314.14
+1.19%

CheckMan Stock Market Overview

Trending Stocks

Name and Ticker
Last
% Change
% Change and Signal
Volume
Signal
9.75
+99.00%
Top Gainers
810,291
Top Gainers
12.3
+98.75%
Top Gainers
749,212
Top Gainers
1580
+90.00%
Top Gainers
1,085,597
Top Gainers
11690
+90.00%
Top Gainers
188,998
Top Gainers
3580
+90.00%
Top Gainers
3,880,889
Top Gainers
2660
+80.00%
Top Gainers
342,913
Top Gainers
9190
+80.00%
Top Gainers
2,538,838
Top Gainers
4005
+80.00%
Top Gainers
526,805
Top Gainers
2110
+80.00%
Top Gainers
311,229
Top Gainers
4530
+80.00%
Top Gainers
183,520
Top Gainers

Red List

Name and Ticker
Last
% Change
% Change and Signal
Volume
Signal
2280
-1620.58%
Top Loosers
476,900
Top Loosers
589
-1100.48%
Top Loosers
880,254
Top Loosers
208
-900.00%
Top Loosers
469,982
Top Loosers
960
-428.13%
Top Loosers
857,090
Top Loosers
82700
-107.62%
Top Loosers
763,022
Top Loosers
2.315
-78.83%
Top Loosers
145,578
Top Loosers
2.16
-50.46%
Top Loosers
25,108,332
Top Loosers
4.69
-47.12%
Top Loosers
128,622
Top Loosers
66.97
-30.42%
Top Loosers
3,895,137
Top Loosers
2.2079
-29.53%
Top Loosers
372,383
Top Loosers

In Today's Headlines

Twenty people in Japan who took an Amgen rare immune-disease drug have died, according to the company that sells the medicine in Japan. U.S. drug regulators had asked Amgen to voluntarily withdraw the drug.
03:37
15 May 2026
Twenty people in Japan who took an Amgen rare immune-disease drug have died, according to the company that sells the medicine in Japan. U.S. drug regulators had asked Amgen to voluntarily withdraw the drug.

Kissei Pharmaceutical, which sells the rare immune-disease drug in Japan, warned doctors to stop prescribing it to new patients.

Carrefour: Full Focus On Margin Improvement
03:34
15 May 2026
Carrefour: Full Focus On Margin Improvement

Carrefour is executing a focused turnaround, emphasizing core geographies, margin expansion, and an asset-light, franchise-driven model. CRRFY's 2030 strategy targets operational efficiency, cost control, and significant growth in convenience stores, especially in France and Spain, to boost margins and cash flow. Dividend growth remains central, with special distributions supplementing ordinary dividends, supported by steady net free cash flow and high-single-digit EPS growth.

Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details
03:34
15 May 2026
Investigation Alert: Biogen Inc. (BIIB) Under Scrutiny - Contact Levi & Korsinsky for Details

New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Biogen Inc. ("Biogen Inc.") (NASDAQ: BIIB) concerning potential violations of the federal securities laws. The stock fell sharply on heavy volume following the May 14 topline data release.

Prestige Consumer Healthcare Inc. (PBH) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today
03:33
15 May 2026
Prestige Consumer Healthcare Inc. (PBH) Under Investigation for Potential Securities Law Violations - Contact Levi & Korsinsky Today

New York, New York--(Newsfile Corp. - May 15, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Prestige Consumer Healthcare Inc. ("Prestige Consumer Healthcare Inc.") (NYSE: PBH) concerning potential violations of the federal securities laws. During the Q3 FY 2026 earnings call, CEO Ron Lombardi stated that Prestige Consumer Healthcare anticipated a 57% adjusted gross margin in Q4.

Here's Why Investors Should Hold On to Cigna Stock for Now
03:31
15 May 2026
Here's Why Investors Should Hold On to Cigna Stock for Now

CI trades below the industry's forward P/E as Evernorth's growth, earnings beats and shareholder returns support its long-term outlook.

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
03:30
15 May 2026
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript

OUTFRONT Media Chief Executive Officer Nick Brien to Participate in the J.P. Morgan 2026 Global Technology, Media and Communications Conference
03:30
15 May 2026
OUTFRONT Media Chief Executive Officer Nick Brien to Participate in the J.P. Morgan 2026 Global Technology, Media and Communications Conference

NEW YORK, May 15, 2026 /PRNewswire/ -- OUTFRONT Media Inc. (NYSE: OUT) announced today that its Chief Executive Officer, Nick Brien, is scheduled to present at the J.P. Morgan 2026 Global Technology, Media and Communications Conference on Tuesday, May 19, 2026, at 2:15 p.m.

CORRECTING and REPLACING Broadway Financial Corporation Announces Results of Operations for First Quarter 2026
03:30
15 May 2026
CORRECTING and REPLACING Broadway Financial Corporation Announces Results of Operations for First Quarter 2026

LOS ANGELES--(BUSINESS WIRE)--Please replace the release dated April 28, 2026 with the following revised version which corrects an error in the calculation of interest on loans in the results of operations. The updated release reads: BROADWAY FINANCIAL CORPORATION ANNOUNCES RESULTS OF OPERATIONS FOR FIRST QUARTER 2026 Broadway Financial Corporation (“Broadway”, “we”, or the “Company”) (NASDAQ: BYFC), parent company of City First Bank, National Association (the “Bank”, and collectively, with the.

Trump touted Palantir on Truth Social after buying the company's stock, records show
03:27
15 May 2026
Trump touted Palantir on Truth Social after buying the company's stock, records show

President Donald Trump scooped up shares of artificial intelligence software maker Palantir weeks before he famously praised the stock on Truth Social. Trump sold as much as $5 million worth of Palantir on Feb. 10.

Coca-Cola Is Not A Value Stock
03:27
15 May 2026
Coca-Cola Is Not A Value Stock

The Coca-Cola Company delivered robust Q1 results with 12% YoY revenue growth and notable North American outperformance. Despite raising EPS guidance to 8%-9%, Coca-Cola left full-year revenue growth projections unchanged at a tepid 4%-5%. Continued insider selling and an expanded forward P/E of 24.73 reinforce concerns about KO overvaluation.